|
$3m for Vectura as asthma target advances
Cabume – Cambridge technology news Vectura has achieved a major milestone in its asthma drug target, triggering a $3m (£1.9m) payment from its unnamed US-based pharmaceutical partner and sending its share price up 5.9 per cent to 76.25p a share. That means Vectura is still on for a … Vectura updates on developmental products and milestones |
View full post on asthma – Google News